Assessment of immunogenicity and efficacy of a Zika vaccine using modified vaccinia Ankara virus as carriers

Assessment of immunogenicity and efficacy of a Zika vaccine using modified vaccinia Ankara virus as carriers

Zika virus (ZIKV) is an emerging mosquito-borne flavivirus that has spread to more than 70 countries worldwide since 2015. Despite active research, there are currently no licensed vaccines or therapeutics. We have previously reported the development of various adenoviral vectored vaccine candidates...

ver descrição completa

Detalhes bibliográficos
Main Authors:	López-Camacho, C, Kim, Y, Abbink, P, Larocca, R, Huiskonen, J, Barouch, D, Reyes-Sandoval, A
Formato:	Journal article
Idioma:	English
Publicado em:	MDPI 2019

Registos relacionados

Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers
Por: César López-Camacho, et al.
Publicado em: (2019-11-01)

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
Por: Moorthy, V, et al.
Publicado em: (2003)

New approaches for improving the immunogenicity of modified vaccinia virus Ankara as a recombinant vaccine vector
Por: Alharbi, N
Publicado em: (2014)

Clinical development of Modified Vaccinia virus Ankara vaccines.
Por: Gilbert, S
Publicado em: (2013)

Clinical development of Modified Vaccinia virus Ankara vaccines
Por: Gilbert, S
Publicado em: (2013)

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
Por: McConkey, S, et al.
Publicado em: (2003)

Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
Por: Rosario, M, et al.
Publicado em: (2010)

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.
Por: Schneider, J, et al.
Publicado em: (1998)

Safety and immunogenicity of IMVAMUNE®, a third-generation vaccine based on the modified vaccinia Ankara (MVA) strain
Por: L. F. Stovba, et al.
Publicado em: (2023-04-01)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
Por: Olga Vladimirovna Orlova, et al.
Publicado em: (2022-09-01)

Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara
Por: Nereida Jiménez de Oya, et al.
Publicado em: (2022-03-01)

Immunogenicity and efficacy of Zika virus envelope domain III in DNA, protein, and ChAdOx1 adenoviral-vectored vaccines
Por: López-Camacho, C, et al.
Publicado em: (2020)

Deletion of fifteen open reading frames from modified vaccinia virus Ankara fails to improve immunogenicity
Por: Alharbi, N, et al.
Publicado em: (2015)

Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity.
Por: Naif Khalaf Alharbi, et al.
Publicado em: (2015-01-01)

Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine—A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Por: Lior Nave, et al.
Publicado em: (2023-08-01)

Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
Por: Kaïdre Bendjama, et al.
Publicado em: (2017-09-01)

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
Por: Goepfert P, et al.
Publicado em: (2012-09-01)

Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial
Por: Milligan, I, et al.
Publicado em: (2016)

Immunogenicity and reactogenicity of novel adenovirus type 26 and modified vaccinia Ankara-vectored Ebola vaccines: A randomized clinical trial
Por: Milligan, I, et al.
Publicado em: (2016)

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.
Por: Mcshane, H, et al.
Publicado em: (2001)

Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction.
Por: Behboudi, S, et al.
Publicado em: (2004)

Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines
Por: César López-Camacho, et al.
Publicado em: (2020-06-01)

Reactogenicity and Immunogenicity Against MPXV of the Intradermal Administration of Modified Vaccinia Ankara Compared to the Standard Subcutaneous Route
Por: Valentina Mazzotta, et al.
Publicado em: (2024-12-01)

Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
Por: Goonetilleke, N, et al.
Publicado em: (2003)

The third generation modified vaccinia Ankara vaccine is effective in preventing the transmission of mpox
Por: Mingwang Shen, et al.
Publicado em: (2024-10-01)

Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations.
Por: Gilbert, S, et al.
Publicado em: (1999)

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus
Por: Juan García-Arriaza, et al.
Publicado em: (2021-08-01)

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.
Por: Jeffrey R Currier, et al.
Publicado em: (2010-11-01)

Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.
Por: Sandhya Vasan, et al.
Publicado em: (2010-01-01)

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.
Por: Hanke, T, et al.
Publicado em: (1998)

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.
Por: Howles, S, et al.
Publicado em: (2010)

Improved Host Range Selection for Recombinant Modified Vaccinia Virus Ankara
Por: Caroline Staib, et al.
Publicado em: (2003-04-01)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
Por: Volker Sandig, et al.
Publicado em: (2013-11-01)

Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates
Por: Leonie Mayer, et al.
Publicado em: (2024-11-01)

Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus
Por: Flavia Chiuppesi, et al.
Publicado em: (2024-02-01)

The Efficacy of Disinfection on Modified Vaccinia Ankara and African Swine Fever Virus in Various Forest Soil Types
Por: Franziska Tanneberger, et al.
Publicado em: (2021-10-01)

Ebola virus – prospects for a novel virus-like-particle-expressing modified vaccinia Ankara-based vaccine
Por: Harriet L. Robinson, et al.
Publicado em: (2018-09-01)

Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
Por: David A Garber, et al.
Publicado em: (2009-01-01)

Correction: Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates
Por: Leonie Mayer, et al.
Publicado em: (2024-12-01)

Transient Host Range Selection for Genetic Engineering of Modified Vaccinia Virus Ankara
Por: C. Staib, et al.
Publicado em: (2000-06-01)